Tube Investments of India (TII) has set up a new manufacturing facility in Andhra Pradesh and a research and development (R&D) center in Chennai. This is part of TII’s plan to expand its medical business, focusing on Active Pharmaceutical Ingredients (API). TII, part of the Murugappa Group, recently entered the medical sector by acquiring Lotus Surgicals, now called TI Medical Pvt Ltd.
TI Medical produces medical and surgical consumables at its advanced plant in Dehradun, Uttarakhand, and is also exploring new MedTech projects. TII’s Executive Chairman, M A M Arunachalam, highlighted the company’s progress, noting the completion of a Kilo lab and ongoing construction of a pilot plant.
In 2023, TII launched 3xper Innoventure Ltd, a venture aimed at contract development and manufacturing of APIs. This new business will support global pharmaceutical and specialty chemical companies with services from drug discovery to commercial manufacturing.
The R&D center in Chennai, employing 50 scientists and chemists, will focus on process and analytical chemistry, as well as technology transfer. Meanwhile, a new plant is being built in Naidupeta, near Chennai, to support large-scale manufacturing. This facility is expected to be operational within the fiscal year.
In FY24, TI Medical earned ₹164 crore in revenue and ₹22 crore in profit before tax since its acquisition. Both TI Medical and 3xper are gearing up for future growth, consolidating resources and expanding their operations and product lines.
